TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03908684

Intervention type: DEVICE
Intervention: Ultrasound Imaging
Description: Ultrasound Spectroscopy assess changes in five different ultrasound spectroscopic parameters over different times during treatment with radiotherapy as predictors of tumour shrinkage and pathologic complete response. Ultrasound parameters investigated will include mid-band fit (related to image intensity),spectroscopic slope (backscatter versus frequency), spectroscopic intercept, histogram fit size and shape parameters which can be used as estimates of scatterer size and concentration.

Intervention type: DEVICE
Intervention: Ultrasound Imaging
Description: Ultrasound Spectroscopy assess changes in five different ultrasound spectroscopic parameters over different times during treatment with radiotherapy as predictors of tumour shrinkage and pathologic complete response. Ultrasound parameters investigated will include mid-band fit (related to image intensity),spectroscopic slope (backscatter versus frequency), spectroscopic intercept, histogram fit size and shape parameters which can be used as estimates of scatterer size and concentration.
Study: NCT00637793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGX267
Description: 2 capsules in the am of each treatment period
Study: NCT03908684

Intervention type: DEVICE
Intervention: Ultrasound Imaging
Description: Ultrasound Spectroscopy assess changes in five different ultrasound spectroscopic parameters over different times during treatment with radiotherapy as predictors of tumour shrinkage and pathologic complete response. Ultrasound parameters investigated will include mid-band fit (related to image intensity),spectroscopic slope (backscatter versus frequency), spectroscopic intercept, histogram fit size and shape parameters which can be used as estimates of scatterer size and concentration.
Study: NCT00793910

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Gabapentin 300 mg taken by mouth thrice daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo (sugar pill) taken by mouth thrice daily for 7 days
Study: NCT02020551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01039116

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity
Description: High-intensity intervention, Experimental. Participating children were invited to attend a 2 week summer day camp at the beginning of each intervention year, and to attend a weekly, 2 hr interactive session for children. Activities provided hand-on experiences preparing and tasting healthy food alternatives, engaging in a range of physical activities and self-esteem boosting via activities that promoted communication and positive behavioral development.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Intensity
Description: Low-intensity intervention, Active comparator. Participants were provided with educational materials 4 times yearly.
Study: NCT03594045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Apixaban is an anticoagulant that works by inhibiting the coagulation factor, Factor Xa.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Apixaban is an anticoagulant that works by inhibiting the coagulation factor, Factor Xa.
Study: NCT00961974

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Ambassador Intervention
Description: Care Ambassador provides additional monthly outreach (by phone or e-mail) to families between clinic visits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Ambassador Intervention
Description: Care Ambassador provides additional monthly outreach (by phone or e-mail) to families between clinic visits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational Intervention
Description: A psychoeducational intervention module is reviewed with the family by the Care Ambassador at each clinic visit. The intervention focuses on incorporating intensive therapy into the daily routine of the child through positive family support for blood glucose monitoring and healthy eating. The intervention modules review positive family communication, realistic expectations, ways to avoid perfectionism and maintain family involvement, prevention of hypoglycemia, avoidance of diabetes-specific family conflict, and approaches to reducing diabetes burnout.
Study: NCT03931434

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Aged Garlic Extract (AGE)
Description: 2400mg of Aged Garlic Extract (AGE)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01511952

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music Intervention
Description: Applied by randomization-live at bassinet in the AM or PM Gato Box, Ocean Disc or parent-selected lullabies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music Intervention
Description: Applied by randomization-live at bassinet in the AM or PM Gato Box, Ocean Disc or parent-selected lullabies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music Intervention
Description: Applied by randomization-live at bassinet in the AM or PM Gato Box, Ocean Disc or parent-selected lullabies
Study: NCT00637793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGX267
Description: 2 capsules in the am of each treatment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NGX267
Description: 2 capsules in the am of each treatment period
Study: NCT01511952

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: Remo Ocean disc Gato box Music therapist's or Parent's preferred lullaby or 'Twinkle'

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: Remo Ocean disc Gato box Music therapist's or Parent's preferred lullaby or 'Twinkle'

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: Remo Ocean disc Gato box Music therapist's or Parent's preferred lullaby or 'Twinkle'
Study: NCT02878993

Intervention type: DEVICE
Intervention: Recording of diaphragm EMG
Description: Recording of diaphragm EMG prior to extubation using surface diaphragm electromyography
Study: NCT04117828

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dates
Description: Phoenix dactylifera, commonly known as date or date palm is a flowering plant species in the palm family, Arecaceae. Dates are the fruit of the date palm tree, which is grown in many tropical regions of the world. Dates provide a wide range of essential nutrients, and has certain protective effects on health of individuals.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dates
Description: Phoenix dactylifera, commonly known as date or date palm is a flowering plant species in the palm family, Arecaceae. Dates are the fruit of the date palm tree, which is grown in many tropical regions of the world. Dates provide a wide range of essential nutrients, and has certain protective effects on health of individuals.
Study: NCT04117828

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dates
Description: Phoenix dactylifera, commonly known as date or date palm is a flowering plant species in the palm family, Arecaceae. Dates are the fruit of the date palm tree, which is grown in many tropical regions of the world. Dates provide a wide range of essential nutrients, and has certain protective effects on health of individuals.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dates
Description: Phoenix dactylifera, commonly known as date or date palm is a flowering plant species in the palm family, Arecaceae. Dates are the fruit of the date palm tree, which is grown in many tropical regions of the world. Dates provide a wide range of essential nutrients, and has certain protective effects on health of individuals.
Study: NCT02249572

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: gamma knife radiosurgery
Description: Leksell Perfection model gamma knife.
Study: NCT00093145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound paclitaxel
Description: Administered by intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin dose was calculated using a modified Calvert formula (creatinine clearance was substituted for GFR): Total dose (mg) = (target AUC) x (creatinine clearance + 25). Note: AUC = 6 was initially targeted, but could be decreased due to toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin®
Description: Administered by IV infusion
Study: NCT03000894

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Description: This CBT-I is a 4 sessions 60-90 minutes group-based therapy administered by a nurse therapist. Each session has 6-8 participants.
Study: NCT02255110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302
Description: TH-302 will be administered at a dose of 300 milligram per square meter (mg/m\^2) by intravenous infusion over 30 minutes on Days 1 and 8 of every 21-day cycle until the evidence of significant treatment-related toxicity or progressive disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will be administered at a dose of 75 mg/m\^2 by intravenous injection (over at least 5 minutes) or by intravenous infusion over 6-96 hours on Day 1 of every 21-day cycle starting 2 to 4 hours after completion of TH-302 administration until the evidence of significant treatment-related toxicity or progressive disease.
Study: NCT01528228

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TENS Treatment with functional or disabled unit
Description: TENS treatment will be standardized and will consist of 20 minute sessions three times per day at the manufacturer's recommended settings for both functional and disabled TENS units.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS Treatment with functional or disabled unit
Description: TENS treatment will be standardized and will consist of 20 minute sessions three times per day at the manufacturer's recommended settings for both functional and disabled TENS units.
Study: NCT01060865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: 150 mg during the first two weeks , 300 mg for another 10 weeks
Study: NCT04257370

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kerecis™ Omega3 Wound
Description: Kerecis™ Omega3 Wound is decellularised, intact fish skin from North Atlantic cod fish. Kerecis™ Omega3 Wound is FDA approved and EU cleared for the treatment of diabetic ulcers, chronic vascular ulcers, venous ulcers, trauma wounds (including abrasions, lacerations, and skin tears), acute surgical wounds (including debridement, amputation, and donor sites), surgical wounds (dehiscence or failed healing after surgery), imminent failure of STSG, and post-injection necrosis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care wound treatment as defined by the local site, including debridement of the wound, standard wound dressing, and proper offloading of the wound site.
Study: NCT02073045

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Receive educational handouts

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lymphedema survey
Description: Ancillary studies
Study: NCT00152295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil/Premarin
Description: 10 mg (2-5mg tablets) asoprisnil and 0.625 mg Premarin tablets, oral daily for 6 months
Study: NCT03877367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper extremity manipulation
Description: An upper extremity (glenohumeral, humeroulnar and radioulnar joints, bilaterally) or a lower extremity (coxofemoral, tibiofemoral, and tibiotalar, bilaterally) manipulation series.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper extremity manipulation
Description: An upper extremity (glenohumeral, humeroulnar and radioulnar joints, bilaterally) or a lower extremity (coxofemoral, tibiofemoral, and tibiotalar, bilaterally) manipulation series.
Study: NCT01198600

Intervention type: DEVICE
Group type: OTHER
Intervention: Habitual contact lens
Description: Hydrogel or silicone hydrogel contact lens per participant's habitual brand and prescription

Intervention type: DEVICE
Group type: OTHER
Intervention: Habitual contact lens
Description: Hydrogel or silicone hydrogel contact lens per participant's habitual brand and prescription

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B contact lens
Description: Commercially marketed silicone hydrogel contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B contact lens
Description: Commercially marketed silicone hydrogel contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: Contact lens cleaning and disinfecting system (ClearCare)
Description: Commercially marketed, hydrogen peroxide-based contact lens care system

Intervention type: DEVICE
Group type: OTHER
Intervention: Contact lens cleaning and disinfecting system (ClearCare)
Description: Commercially marketed, hydrogen peroxide-based contact lens care system
Study: NCT02950493

Intervention type: OTHER
Group type: OTHER
Intervention: perflutren lipid microsphere
Description: Definity and Lumason are tools for diagnosis used in echocardiography. Compare activated Definity or Lumason with compressed Definity or Lumason.
Study: NCT03799575

Intervention type: BEHAVIORAL
Intervention: Transmission Electron Microscopy analysis
Description: Morphology of two vitreal side of Internal Limiting Membrane in contact
Study: NCT04682639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod
Description: Participants will receive etrasimod tablet by mouth, once daily during the 24-week Double-Blind and 28-week Extension Treatment Periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod
Description: Participants will receive etrasimod tablet by mouth, once daily during the 24-week Double-Blind and 28-week Extension Treatment Periods.
Study: NCT02744924

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Description: The intervention is comprised of 5 steps:~1. Goal setting: Over a step-counter (smartphone app) participants learn about their daily average step count. They are coached to set individual goals~2. Fitness assessment: To recommend suitable frequency and intensity of walking program using mapped trails~3. Structured walking groups: Promoted and communicated via app. Participants can additionally organize walking groups of their own.~4. Feedback: Participants will see individual and group data over the step-counter app, and they can communicate with others via a communication app. They will be incentivized to reach goals through a gamification approach.~5. Invite friends: After 12 weeks, participants are encouraged to invite people who fulfil the inclusion criteria to join the project
Study: NCT02879838

Intervention type: OTHER
Intervention: Blood sample
Description: Biobank. Analysis of cytokines and DNA polymorphisms

Intervention type: OTHER
Intervention: Blood sample
Description: Biobank. Analysis of cytokines and DNA polymorphisms

Intervention type: OTHER
Intervention: Blood sample
Description: Biobank. Analysis of cytokines and DNA polymorphisms
Study: NCT06015776

Intervention type: OTHER
Intervention: Gender
Description: Differences between men and women will be observed

Intervention type: OTHER
Intervention: Gender
Description: Differences between men and women will be observed
Study: NCT04454671

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous neuromodulation (NMPE)
Description: It is a technique based on electrical stimulation of a peripheral nerve through an ultrasound-guided needle or a muscle at a motor site. The stimulation is performed with low or medium frequency currents in which a sensory and / or motor response is sought by stimulating the peripheral nerve

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound-guided dry needling
Description: Dry needling technique under ultrasound imaging in order to ensure accurate placement of the needle for optimum results.
Study: NCT03715634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INDV-6200
Description: Subjects will be randomized in a 3:1 ratio to receive either depot buprenorphine or volume-matched placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized in a 3:1 ratio to receive either depot buprenorphine or volume-matched placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL Buprenorphine
Description: All subjects will receive SL buprenorphine as non-investigational IMP to confirm tolerability

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SL Buprenorphine
Description: All subjects will receive SL buprenorphine as non-investigational IMP to confirm tolerability

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalorex
Description: Both Periods will include series of nalorex administrations to antagonize potential opioid effects from buprenorphine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nalorex
Description: Both Periods will include series of nalorex administrations to antagonize potential opioid effects from buprenorphine
Study: NCT01545999

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Brain Stimulation via Transcranial Magnetic Stimulation
Description: PAS-25 will consist of 180 PNS delivered to right median nerve, each paired with a single TMS pulse delivered over left DLPFC with an interstimulus interval of 25 ms. This ISI was designed to generate approximately synchronous arrival of both inputs in M1 and was reported to markedly enhance TMS-induced MEP following PAS-25.~Patients with schizophrenia will be asked to continue with a 2-week course (5 days/week) of daily PAS-25 or PAS-100 to assess potential of a repetitive course of PAS-25 on enhancing working memory in patients with Schizophrenia. One and seven days after the 2-week course PAS-25 or PAS-100, patients with schizophrenia will be assessed with the N-back task.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brain Stimulation via Transcranial Magnetic Stimulation
Description: PAS-25 will consist of 180 PNS delivered to right median nerve, each paired with a single TMS pulse delivered over left DLPFC with an interstimulus interval of 25 ms. This ISI was designed to generate approximately synchronous arrival of both inputs in M1 and was reported to markedly enhance TMS-induced MEP following PAS-25.~Patients with schizophrenia will be asked to continue with a 2-week course (5 days/week) of daily PAS-25 or PAS-100 to assess potential of a repetitive course of PAS-25 on enhancing working memory in patients with Schizophrenia. One and seven days after the 2-week course PAS-25 or PAS-100, patients with schizophrenia will be assessed with the N-back task.
Study: NCT02905877

Intervention type: OTHER
Intervention: Behavioural study
Description: reaching studies and other behavioural studies.

Intervention type: OTHER
Intervention: Behavioural study
Description: reaching studies and other behavioural studies.

Intervention type: OTHER
Intervention: Behavioural study
Description: reaching studies and other behavioural studies.
Study: NCT02440672

Intervention type: DEVICE
Intervention: JOURNEY™ II CR Total Knee System (J II CR TKS)
Description: TKA with Journey II CR Total Knee System
Study: NCT03640754

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: G-CSF injected subcutaneously 3 times (Days 0, 28, 56)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/Saline
Description: Placebo/saline injected subcutaneously 3 times (Days 0, 28, 56)
Study: NCT04682639

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive etrasimod matching placebo tablet by mouth, once daily during the 24-week Double-Blind Treatment Period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etrasimod
Description: Participants will receive etrasimod tablet by mouth, once daily during the 28-week Extension Treatment Period.
Study: NCT05329402

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Disposable Powered Articulating Endoscopic Linear Cutter Stapler
Description: Using the Disposable Powered Articulating Endoscopic Linear Cutter Stapler according to routine treatment
Study: NCT01383954

Intervention type: DRUG
Group type: OTHER
Intervention: Diclofenac Gel
Description: Diclofenac gel 4 grams (g) applied topically 4 times daily (QID) to the affected knee(s) for up to 4 weeks. Participants took a maximum dosage of 32 g/day.
Study: NCT04144387

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myelogram
Description: Two additional myelograms will be performed comparing to standard of care.
Study: NCT00411762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHY906
Study: NCT05329402

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ECHELON Flex Powered Articulating Endoscopic Linear Cutters
Description: Using the ECHELON Flex Powered Articulating Endoscopic Linear Cutters according to routine treatment
Study: NCT02313077

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-filo
Description: One 0.5 mL intramuscular (IM) injection of 1E8 (50%Tissue Culture Infectious Dose \[TCID50\]) on Day 1 (Groups 1 and 2), or on Day 29 (Group 3), or on Day 57 (Group 4), or on Day 15 (Group 5).
Study: NCT04793828

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Velibra
Description: Velibra is an internet-based cognitive behavioral therapy program developed by GAIA AG. It consists of six modules which are meant to be completed over a span of 6 weeks. The first module educates participants about anxiety and the treatment program. The second module focuses on cognitive techniques for dealing with anxiety. In the third module, relaxation techniques are practiced. The fourth module encourages the participant to practice non-anxious behaviors. In the fifth module, the central topic is the experience of social situations in non-anxious ways. The sixth and final module consists of a summary and recapitulation of the most important content.